A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2011
10/19/2011	CN102219859A Fusion protein for antagonizing angiogenesis inducible factor and application thereof
10/19/2011	CN102219856A Vascular Endothelial Growth Factor (VEGF) acceptor 2/CD3 bispecific single-chain antibody
10/19/2011	CN102219855A High-affinity anti-EGFR (epidermal growth factor receptor) monoclonal antibody
10/19/2011	CN102219854A Monoclonal antibody of anti-human PIGF (placental growth factor) protein as well as preparation method and application thereof
10/19/2011	CN102219835A Long peptide based on HCA587 antigen and its application in preparing antitumor drugs
10/19/2011	CN102219822A Ganoderic acid T amide derivative TLTO-A and synthetic method and application thereof
10/19/2011	CN102219821A Cardiac glycoside compounds and antitumor application thereof
10/19/2011	CN102219812A Tumor targeting deoxyglucose composite drug and preparation method thereof
10/19/2011	CN102219811A CA-4 derivatives and preparation method and medicinal application thereof
10/19/2011	CN102219784A Heteroaryl urea derivatives useful for inhibiting CHKl
10/19/2011	CN102219772A Cortex pseudolaricis acid complex with bioactivity and preparation method thereof
10/19/2011	CN102219768A Perylenequinone compounds and their extraction and separation method and use
10/19/2011	CN102219755A Micromolecule selective depressant for STAT3 (Signal transducer and activator of transcription 3), as well as preparation method and applications thereof
10/19/2011	CN102219751A Pentadienone-containing 4-substituted quinazoline derivative, preparation method and use thereof
10/19/2011	CN102219745A 2-aryl substituted benzimidazole derivatives, as well as preparation method and application thereof
10/19/2011	CN102219724A Pyrrolidone compound as well as preparation method and applications thereof
10/19/2011	CN102219717A N-phenyl aryl formamide derivative, preparation method thereof and use thereof
10/19/2011	CN102219705A Crystallization process of columnar crystal of L-serine and application of columnar crystal
10/19/2011	CN102219670A Linear chain polyketone compounds and application thereof
10/19/2011	CN102218148A Use of epstein-barr virus miR-BART1-5p antisense oligonucleotide in preparing drugs for treating nasopharyngeal carcinoma
10/19/2011	CN102218147A Use of epstein-barr virus miR-BART7 antisense oligonucleotide in preparing drugs for treating nasopharyngeal carcinoma
10/19/2011	CN102218144A Method for regulating content of micro-ribonucleic acids in organism and use thereof
10/19/2011	CN102218143A Water dispersion type carbon nano-tube freeze-dried powder and preparation method thereof
10/19/2011	CN102218140A Tumor resistance effect of medicine combination of salvianolic acid B and coxib medicaments
10/19/2011	CN102218120A Prescription of compound capsule for strengthening healthy energy and eliminating tumor and manufacture method thereof
10/19/2011	CN102218100A Effervescent tablet for treating cervical cancer and gynecological inflammation and preparation method thereof
10/19/2011	CN102218098A Pharmaceutical kit for treating breast cancer and new purpose thereof
10/19/2011	CN102218097A Effective part of spreading hedyotis herb and preparation method thereof
10/19/2011	CN102218087A Method for preparing total flavone extracts of pagoda flower
10/19/2011	CN102218075A Composition for down-regulating pro-inflammatory markers
10/19/2011	CN102218070A Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
10/19/2011	CN102218069A Applicationof A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments
10/19/2011	CN102218068A Application of PPARgamma stimulant 15d-PGJ2 to preparation of targeting liver cancer stem cell drugs
10/19/2011	CN102218065A New application of aloperin in pharmacy
10/19/2011	CN102218058A Application of sparstolenin B as TLR2 (Toll-like receptor 2)/TLR4 (Toll-like receptor 4) antagonist in pharmacy
10/19/2011	CN102218053A Application of luteolin in preparation of medicaments for inhibiting angiogenesis
10/19/2011	CN102218037A Ifosfamide liposome combination medicament, and formula, preparation method and purpose thereof
10/19/2011	CN102218033A Formula, preparation method and use of alprostadil liposome combined medicament
10/19/2011	CN102218028A Antisense oligonucleotide injection for treating liver cancer and preparation method thereof
10/19/2011	CN102218027A Polymer micelle lyophilized agent encapsulating insoluble antitumor drug
10/19/2011	CN102217757A Plant superoxide dismutase buccal tablets and preparation method thereof
10/19/2011	CN101845026B 5-(4-chlorophenylmethyl)-4-tertiary butyl thiazole derivatives and preparation method and application thereof
10/19/2011	CN101781269B 4-tertiary butyl-2-(nitrobenzyl imino) thiazole derivative as well as preparation method and application thereof
10/19/2011	CN101696205B 3-(substituted xylylenimine-2-yl)-2,6-dioxopiperidine polymorph and pharmaceutical composition
10/19/2011	CN101695476B Method for preparing medical nanoparticles
10/19/2011	CN101570515B Curcumin substituted uracil derivative, preparation method and use thereof
10/19/2011	CN101555291B Extraction and separation technology of ginseng polysaccharides
10/19/2011	CN101541339B A percutaneous intratumoral injection composition for treating thyroma
10/19/2011	CN101528215B Compositions of chk1 inhibitors and cyclodextrin
10/19/2011	CN101384577B Novel coumarin derivative having antitumor activity
10/19/2011	CN101223165B Ethanolamine salt of N- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide
10/18/2011	US8039585 for use in treatment and prevention of vision defects and cell proliferative disorders
10/18/2011	US8039488 Methods and compositions for inhibition of angiogenesis
10/18/2011	US8039464 Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases
10/18/2011	US8039460 CGRP receptor antagonists
10/18/2011	US8039454 Macrolide compounds with antibiotic and antineoplastic properties
10/18/2011	US8039444 Antisense permeation enhancers
10/18/2011	US8039000 Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
10/18/2011	US8038999 Breast cancer eradication program
10/18/2011	CA2673449C A combination comprising combretastatin and anticancer agents
10/18/2011	CA2649549C Methods of treating cell proliferative disorders by using pyrimidinediamine compounds
10/18/2011	CA2589894C Radionuclide-chitosan complex having an improved stabilized gelatin in administering them to the body and their preparation method
10/18/2011	CA2560058C A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
10/18/2011	CA2552107C Pyrrolotriazine compounds as kinase inhibitors
10/18/2011	CA2515663C Chitosan-based transport system
10/18/2011	CA2503730C Cytarabine monophosphate prodrugs
10/18/2011	CA2498210C Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
10/18/2011	CA2494049C Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
10/18/2011	CA2484038C Estrogen receptor modulators
10/18/2011	CA2478813C Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
10/18/2011	CA2475312C N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
10/18/2011	CA2465156C Il-21 antagonists
10/18/2011	CA2453441C Lyophilizing composition of drug-encapsulating polymer micelle and method for preparation thereof
10/18/2011	CA2446189C Peptides and related molecules that bind to tall-1
10/18/2011	CA2443950C Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
10/18/2011	CA2440644C Inhibitors of integrin .alpha.v.beta.6
10/18/2011	CA2403218C Embolic compositions
10/18/2011	CA2398018C Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/18/2011	CA2228944C Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides
10/13/2011	WO2011127472A1 Compositions and methods for providing hematopoietic function
10/13/2011	WO2011127470A1 Compositions and methods for providing hematopoietic function without hla matching
10/13/2011	WO2011127465A2 Ship inhibitors and uses thereof
10/13/2011	WO2011127406A2 Acridines as inhibitors of haspin and dyrk kinases
10/13/2011	WO2011127405A1 Methods and compositions for enhanced delivery of compounds
10/13/2011	WO2011127393A2 Variants of ancestral uricases and uses thereof
10/13/2011	WO2011127388A2 Inverse agonists and neutral antagonists for the tsh receptor
10/13/2011	WO2011127324A2 Antibodies to cd122
10/13/2011	WO2011127232A2 Substituted androst-4-ene diones
10/13/2011	WO2011127222A1 Diagnosis and treatment of melanoma through nuak2 assessment and modulation
10/13/2011	WO2011127202A2 Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
10/13/2011	WO2011127129A1 Methods of treating cancer
10/13/2011	WO2011127070A2 IRE-1α INHIBITORS
10/13/2011	WO2011127061A1 Enhancement of radiation therapy by targeted high-z nanoparticles
10/13/2011	WO2011127058A2 Biomarkers for mdm2 inhibitors for use in treating disease
10/13/2011	WO2011126864A2 Cancer treatment with recombinant vector
10/13/2011	WO2011126853A2 Prevention or delay of onset of oral mucositis
10/13/2011	WO2011126821A2 Indolyl or indolinyl hydroxamate compounds
10/13/2011	WO2011126733A2 Combination therapies: inhibitors of gaba transaminase and nkcc1
10/13/2011	WO2011126409A1 Telomerase inhibitors and a method for the preparation thereof
10/13/2011	WO2011126010A1 Cancer cell-specific cell-penetrating peptide and use thereof

1 ... 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 ... 2211